Table 1.
Clinical data during HCV antiviral treatment regimens
| Rx Week Date |
Cr (umol/L) | eGFR | INR | Bili T (umol/L) | Bili D (umol/L) | ALT (U/L) | Alb (g/L) | MELD | CTP Score | HCV RNA IU/mL |
Cryocrit | Hg (g/L) | RBV mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Antiviral therapy #1—SOF/RBV—24 weeks | |||||||||||||
| 0 05/2014 |
222 | 27 | 1.9 | 61 | 14 | 135 | 27 | 26 | 13 | 4.11×105 | 5% | 77 | 200 EOD |
| 4 06/2014 |
107 | 63 | 1.5 | 54 | – | 33 | 42 | 16 | 9 | <LLD* | − | 93 | 400 EOD |
| 12 08/2014 |
95 | 72 | 1.3 | 48 | 7 | 26 | 47 | 13 | 8 | neg | Not detected | 101 | 200 daily |
| 24 11/2014 |
87 | 80 | 1.3 | 39 | − | 24 | 38 | 16 | 8 | neg | − | 127 | 200 BID |
| 3 weeks post Rx 12/2014 |
278 | 21 | 1.4 | 39 | − | 229 | 38 | 25 | 10 | 1.45×105 | 15% | 104 | – |
| Antiviral therapy #2—SOF/LDV/RBV—12 weeks | |||||||||||||
| 0 01/2015 |
152 | 40 | 1.4 | 61 | 10 | 92 | 39 | 19 | 10 | – | – | 116 | 600 BID |
| 4 02/2015 |
170 | 37 | 1.3 | 115 | 10 | 28 | 34 | 22 | 10 | – | – | 117 | 600 BID |
| 12 04/2015 |
118 | 57 | 1.3 | 130 | 8 | 18 | 35 | 19 | 10 | – | – | 99 | 600 BID |
| 12 weeks post Rx 08/2015 |
131 | 51 | 1.2 | 34 | 5 | 20 | 36 | 14 | 8 | Not detected | Not detected | 117 | – |
*<LLD defined as below the linear range of the assay, which is <15 IU/mL.
BID, twice daily; Bili D, direct bilirubin; Bili T, total bilirubin; Cr, creatinine; CTP, Child-Turcotte-Pugh; Date, mm/yyyy; eGFR, estimated glomerular filtration rate (mL/min/1.73 m2); EOD, every other day; HCV, hepatitis C; INR, international normalisation ratio; LLD, lower limit of detection; MELD, model for end-stage liver disease, RBV, ribavirin; Rx, treatment.